Get the Stockscreener App
210.02
0.40%
-0.85
After Hours:
210.50
0.48
+0.23%
Revolution Medicines Inc stock is traded at $210.02, with a volume of 884.36K.
It is down -0.40% in the last 24 hours and up +8.56% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$210.87
Open:
$209.01
24h Volume:
884.36K
Relative Volume:
0.35
Market Cap:
$45.01B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-29.69
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+1.03%
1M Performance:
+8.56%
6M Performance:
+107.55%
1Y Performance:
+439.20%
1-Day Range:
$207.48
$211.75
1-Week Range:
$200.53
$212.06
52-Week Range:
$39.17
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, MRNA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Revolution (RVMDW) Price and Levels: Advances 4.09% to $12.59 in Latest Trading; Technical Focus: the $11.96 to $13.22 Range Remains in Focus in the Available RecordBollinger Walk - Vinanet
Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative
Revolution Medicines stock hits all-time high at 208.77 USD - Investing.com
Revolution Medicines stock hits all-time high at 208.77 USD By Investing.com - Investing.com Australia
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026 (XLV:NYSEARCA) - Seeking Alpha
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring Growth Potential with RAS-Targeted Therapies - DirectorsTalk Interviews
State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD - MarketBeat
S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (MEX:RVMD) Shiller PE Ratio : (As of Aug. 16, 2026) - GuruFocus
Revolution Medicines Inc Stock Baskets - GuruFocus
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Yahoo Finance
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines - Stock Titan
Top Revolution Medicines (RVMDW) Competitors 2026 - MarketBeat
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing - Stock Titan
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - Yahoo Finance
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - Yahoo Finance
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - Yahoo Finance
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - MarketBeat
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - BioSpace
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revolution Medicines Inc Stock (RVMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cislini Jeff | General Counsel |
Aug 21 '26 |
Sale |
209.24 |
56,894 |
11,904,247 |
55,907 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Option Exercise |
4.73 |
80,000 |
378,400 |
347,330 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Sale |
209.20 |
80,000 |
16,735,887 |
267,330 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Sale |
209.20 |
6,000 |
1,255,219 |
61,424 |
1.22%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):